Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Down 55.8% in October – MarketBeat

This post was originally published on this site

Global X Genomics & Biotechnology ETF (NASDAQ:GNOMGet Rating) was the target of a large decrease in short interest in October. As of October 31st, there was short interest totalling 31,900 shares, a decrease of 55.8% from the October 15th total of 72,100 shares. Based on an average daily trading volume, of 110,400 shares, the short-interest ratio is currently 0.3 days.

Global X Genomics & Biotechnology ETF Price Performance

Shares of GNOM traded up $0.52 during trading hours on Friday, reaching $13.80. The stock had a trading volume of 2,169 shares, compared to its average volume of 138,377. Global X Genomics & Biotechnology ETF has a 52 week low of $10.48 and a 52 week high of $21.80. The firm has a 50-day moving average of $12.96 and a 200 day moving average of $13.10.

Hedge Funds Weigh In On Global X Genomics & Biotechnology ETF

Large investors have recently added to or reduced their stakes in the company. Elmwood Wealth Management Inc. increased its holdings in Global X Genomics & Biotechnology ETF by 7.3% during the 2nd quarter. Elmwood Wealth Management Inc. now owns 62,450 shares of the company’s stock worth $763,000 after purchasing an additional 4,225 shares in the last quarter. Sightline Wealth Advisors LLC increased its holdings in Global X Genomics & Biotechnology ETF by 105.1% during the 2nd quarter. Sightline Wealth Advisors LLC now owns 40,962 shares of the company’s stock worth $501,000 after purchasing an additional 20,987 shares in the last quarter. Stratos Wealth Partners LTD. bought a new position in Global X Genomics & Biotechnology ETF during the 1st quarter worth about $214,000. McGuire Investment Group LLC increased its holdings in Global X Genomics & Biotechnology ETF by 0.4% during the 2nd quarter. McGuire Investment Group LLC now owns 525,886 shares of the company’s stock worth $6,426,000 after purchasing an additional 1,900 shares in the last quarter. Finally, Private Advisor Group LLC increased its holdings in Global X Genomics & Biotechnology ETF by 22.5% during the 1st quarter. Private Advisor Group LLC now owns 833,786 shares of the company’s stock worth $12,532,000 after purchasing an additional 153,000 shares in the last quarter.

About Global X Genomics & Biotechnology ETF

(Get Rating)

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Global X Genomics & Biotechnology ETF, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Global X Genomics & Biotechnology ETF wasn’t on the list.

While Global X Genomics & Biotechnology ETF currently has a “N/A” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

This post was originally published on *this site*